Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 7;58(1):90.
doi: 10.3390/medicina58010090.

Intravesical Therapy for Non-Muscle-Invasive Bladder Cancer: What Is the Real Impact of Squamous Cell Carcinoma Variant on Oncological Outcomes?

Guglielmo Mantica  1 , Francesco Chierigo  1 , Rafaela Malinaric  1 , Salvatore Smelzo  2 , Francesca Ambrosini  1 , Martina Beverini  1 , Giovanni Guano  1 , Alberto Caviglia  1 , Lorenzo Rigatti  2 , Aldo Franco De Rose  1 , Alessandro Tafuri  3 , Davide De Marchi  2 , Franco Gaboardi  2 , Nazareno Suardi  1 , Carlo Terrone  1
Affiliations

Intravesical Therapy for Non-Muscle-Invasive Bladder Cancer: What Is the Real Impact of Squamous Cell Carcinoma Variant on Oncological Outcomes?

Guglielmo Mantica et al. Medicina (Kaunas). .

Abstract

Background and Objectives: To evaluate the oncological impact of squamous cell carcinoma (SCC) variant in patients submitted to intravesical therapy for non-muscle-invasive bladder cancer (NMIBC). Materials and Methods: Between January 2015 and January 2020, patients with conventional urothelial NMIBC (TCC) or urothelial NMIBC with SCC variant (TCC + SCC) and submitted to adjuvant intravesical therapies were collected. Kaplan-Meier analyses targeted disease recurrence and progression. Uni- and multivariable Cox regression analyses were used to test the role of SCC on disease recurrence and/or progression. Results: A total of 32 patients out of 353 had SCC at diagnosis. Recurrence was observed in 42% of TCC and 44% of TCC + SCC patients (p = 0.88), while progression was observed in 12% of both TCC and TCC + SCC patients (p = 0.78). At multivariable Cox regression analyses, the presence of SCC variant was not associated with higher rates of neither recurrence (p = 0.663) nor progression (p = 0.582). Conclusions: We presented data from the largest series on patients with TCC and concomitant SCC histological variant managed with intravesical therapy (BCG or MMC). No significant differences were found in term of recurrence and progression between TCC and TCC + SCC. Despite the limited sample size, this study paves the way for a possible implementation of the use of intravesical BCG and MMC in NMIBC with histological variants.

Keywords: adjuvants; neoplasm recurrence; regression analysis; squamous cell carcinoma; urinary bladder neoplasms.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier analysis showing estimates of disease recurrence in TCC and TCC + SCC patients treated with MMC (log-rank p = 0.448). TCC = Conventional Urothelial non-muscle-invasive bladder cancer. SCC = Squamous Cell Carcinoma.
Figure 2
Figure 2
Kaplan–Meier analysis showing estimates of disease recurrence in in TCC and TCC + SCC patients treated with BCG (log-rank p = 0.532).
Figure 3
Figure 3
Kaplan–Meier in BCG vs. MMC in TCC patients (log-rank, p = 0.271). BCG = Bacillus Calmette Guerin. MCC = Mitomycin C.
Figure 4
Figure 4
Kaplan–Meier in TCC + SCC patients (log-rank, p = 0.759).
See this image and copyright information in PMC

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Abdou Hassan W., Shalaby E., Abo-Hashesh M., Ibrahim Ali R. Evaluation of the Expression of HER2 and c-KIT Proteins as Prognostic Markers in Superficial Bladder Urothelial Carcinoma. Res. Rep. Urol. 2021;13:197–206. doi: 10.2147/RRU.S296974. - DOI - PMC - PubMed
    1. Peyrottes A., Ouzaid I., Califano G., Hermieu J.-F., Xylinas E. Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer. Medicina. 2021;57:769. doi: 10.3390/medicina57080769. - DOI - PMC - PubMed
    1. Babjuk M., Burger M., Compérat E., Gontero P., Liedberg F., Masson-Lecomte A., Mostafid A.H., Palou J., van Rhijn B.W.G., Rouprêt M., et al. EAU Guidelines 2021 on Non-Muscle-Invasive Bladder Cancer. [(accessed on 15 August 2021)]. Available online: www.uroweb.org.
    1. Sawazaki H., Arai Y., Ito Y., Sato K., Tsuda H., Yamaga T., Sakurai H. Expression of L-Type Amino Acid Transporter 1 is a Predictive Biomarker of Intravesical Recurrence in Patients with Non-Muscle Invasive Bladder Cancer. Res. Rep. Urol. 2021;13:603–611. doi: 10.2147/RRU.S326249. - DOI - PMC - PubMed

MeSH terms